Phase 1 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- A tissue sample (biopsy) must have confirmed a diagnosis of rectal adenocarcinoma (a specific type of rectal cancer).
- The cancer must be at a specific stage — classified as T2-3, N0-1, M0 — meaning it has grown into but not beyond the rectal wall, with no or limited nearby lymph node involvement and no spread to other parts of the body. Staging is confirmed through MRI of the pelvis and a CT scan of the chest and abdomen (or a PET-CT scan as an alternative).
- Participants must be willing to undergo MRI scans during the trial.
- Participants must be 18 years of age or older.
- Participants must have a general health status rated as ECOG 0 or 1, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site).
- Participants must have an estimated life expectancy of at least 12 months.
- Participants must have blood and organ function results within acceptable ranges, including adequate white blood cell counts, platelet counts, and liver function levels (confirm with trial site for specific values).
- Participants must be medically able to tolerate the chemotherapy medicines used in the trial — capecitabine before the main treatment phase, and either FOLFOX, 5-FU, or capecitabine afterward.
- Participants must be willing and able to sign an informed consent form. Translation services will be provided where possible to support inclusion of people from diverse backgrounds.
Who may not be able to join:
- People who have already received treatment for rectal cancer.
- People whose rectal cancer directly involves the anal canal (cancer that is close to but not inside the anal canal may still be considered).
- People who are currently taking part in another clinical trial involving an experimental treatment.
- People who have previously had radiation therapy to the pelvic area.
- People who have had another cancer that was actively treated within the past 3 years, not including certain common skin cancers (non-melanoma skin cancer).
- People with serious uncontrolled health conditions, such as an active infection, severe heart problems, uncontrolled heart rhythm issues, or mental health or social circumstances that could make it difficult to follow the trial requirements.
- People with any condition or significant health problem that, in the treating doctor's judgment, would make the main radiation treatment unsafe to deliver.
- People who are pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joshua Meyer, Fox Chase Cancer Center
Phone: 215-728-2667
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
MTD will be evaluated by monitoring the rate of dose limiting toxicities (DLTs) defined as acute Grade 2+ gastrointestinal toxicity probably or definitely related to radiation.; Feasibility of a rectal boost that targets at least 90% of the rectal planning tumor volume with the 80% prescribed dose while limiting the outer 3 mm of the rectal wall to no more than 50% of the prescription dose delivered to 0.1cc.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.